BioNetwork West 2015 (past event)
October 26 - 28, 2015
Contact Us: 1.888.482.6012
Ken Lebioda
SVP Business & Market Development
Resverlogix
Change Compliance to Regulatory
Friday, March 10th, 2017
11:45 Biotech Spotlight: Resverlogix
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.